Company / Cash & Equivalents
Odyssey Health, Inc. Cash & Equivalents History
FY2015-FY2021 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$556.6K
FY2021
5-year range
$390 / $556.6K
FY2017-FY2021
Trend
+233.1%
vs FY2020
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents changed +233% YoY in FY2021, a notable deviation from the 5-year average annual change of +8667%.
Based on SEC 10-K filings.
$556,584 in FY2021 with a 5-year CAGR of +203.0%.
Improved from $390 to $556,584 over the past 3 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- +203.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +203.0%, indicating consistent growth.
- In FY2021, cash & equivalents increased 233.1% year-over-year.
- Lowest cash & equivalents in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score -147.76 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2021 | $556.6K | +233.1% |
| FY2019 | $167.1K | +42744.9% |
| FY2018 | $390 | -97.1% |
| FY2017 | $13.4K | +515.6% |
| FY2016 | $2.2K | -59.2% |
| FY2015 | $5.3K | - |
As of FY2021 · SEC 10-K · Updated Jun 29, 2026